Enhancing erythropoietin therapy in ischaemia-reperfusion injury of heart and kidney

由于血流量不足引起的心脏病发作和肾脏疾病是常见的发病原因，治疗方案也很差。促红细胞生成素（epo）是一种有用的新疗法，但在人类中使用仍有一些注意事项。它可能会在修复过程中造成过多的疤痕。促红细胞生成素与消炎药一起使用可以减少疤痕，对长期健康有益。我们计划仔细定义损伤和修复的生物分子途径，以更好地规划这种治疗用于人类。

Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.